This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our Privacy Policy.

b1_bannerpc.jpg b1_bannerph.jpg

  • Who we are

    We believe every life is a noble sovereign kingdom.Career builds the castle, family passes down the legacy, and achievements enrich the treasure. Yet health is the eternal king that rules all.

    This is the essence of Kingfriend.


    b1_img01.jpg

  • We walk beside you as a loyal, quiet friend.

    Like gentle leaves that shelter and uphold, we guard your health with science, premium quality and steadfast dedication.

    We stand by your side to sustain your inner vitality, protect your well-being, and accompany you toward a long, wonderful life.


    b1_img02.jpg

What we do

Kingfriend operates state-of-the-art, fully automated high-speed production lines, featuring integrated isolator technology.

Kingfriend stands as one of the few Chinese enterprises to have successfully passed rigorous quality inspections by major global regulatory authorities, including the US FDA, EU EDQM, Japan PMDA, Brazil ANVISA, and UK MHRA.


  • Sterile Injections

    • Integrated R&D, production and sales of generic sterile injections covering oncology, anesthesia, cardiovascular and anti-infective fields.

  • Biosimilars

    • Independent biosimilar R&D platform, focusing on monoclonal antibodies and achieving FDA & EU regulatory approvals.

  • Innovatives

    • Dedicated to innovative drug R&D, focusing on first-in-class and best-in-class biological new drugs.
b1_img07.jpg b1_img07ph.jpg

What we offer

We’ve got your injectable formats covered.

Vial · PFS · Cartridge · Pen

From hospital use to patient self-injection — we deliver them all.


Since
2025

Benefits

Sunshine Culture,High-Quality Products, Excellent Operations, Shared Development

  • 2025

  • 2023

  • 2021

  • 2019

  • 2017

  • 2016

  • 2012

  • 2000

  • 1987

  • 2025

    European Market Entry

    Found Evumed to officially enter the European pharmaceutical market.

  • 2023

    R&D Platform

    Establish a comprehensive biosimilar research and development platform.

  • 2021

    Biosimilar pipeline

    Become the first Chinese company to obtain US FDA biosimilar approval for Adalimumab Injection.

  • 2019

    US Marketing team

    Acquire Meitheal to build its in-house US marketing team

  • 2017

    Capital Market Listing

    Land its listing on the Main Board of the Shanghai Stock Exchange.

  • 2016

    Kindos

    Acquire Kindos

  • 2012

    R&D Building Completion

    Complete construction of the dedicated R&D building to support innovation.

  • 2000

    Pharmaceutical Export Launch

    Initiate global pharmaceutical exports and established partnerships with multinational corporations.

  • 1987

    Pioneer in Heparin

    Rank among China’s earliest heparin manufacturer with complete industrial chain layout.